New drug cocktail aims to revive immunotherapy in tough lung cancers
NCT ID NCT05013450
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This early-stage trial tests whether adding two anti-inflammatory drugs (dupilumab and anakinra) to standard immunotherapy can help shrink tumors in people with advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. About 33 adults will receive the combination to check safety and see if tumors respond. The goal is to overcome resistance to current treatments, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tisch Cancer Institute, Mount Sinai Hospital
New York, New York, 10003, United States
Conditions
Explore the condition pages connected to this study.